Intact human osteocalcin purified from femoral bones as well as tryptic fragments of the intact molecule [amino acids (aa) 1-19, 20-43, and 45-49] were used to raise and screen monoclonal antibodies (MAbs). A two-site ELISA for measurement of human osteocalcin in serum was developed with use of these MAbs. A MAb recognizing midregion human osteocalcin (aa2O-43) was used as capture antibody, and an NH2 terminus (aa7-19)-specific peroxidase-conjugated MAb was used for detection. Human osteocalcin obtained from bone was used for calibration, and parallelism was observed for osteocalcin from serum samples, NH2-terminal midfragments (aal-43), and synthetic human osteocalcin. Both inter-and intraassay variations were <7%. Serum osteocalciri in healthy premenopausal-women (ii = 49) was 18.3 ± 4.2 g/L (mean ± SD) and 28.6 ± 9.7 g/L in early postmenopausaI women (n = 114). The mean serum concentration (n = 10) decreased by 10% after 7 days of storage at 4 #{176}C, whereas the concentration of intact human osteocalcin was reduced 63%. The NMlDTM ELISA and an IRMA measuring intact human osteocalcin were used to monitor the effect of hormone replacement therapy in a retrospective study. A significant decrease to the premenopausal concentration was detected only in the N-MID ELISA.
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Indexing Terms: hormone replacement therapy/menopause/fernoral bones/NH2-terminai midfragment
Osteocalcin bone Gla protein is a bone-specific prothin and the major noncollagenous protein in the bone matrix (1, 2) . The synthesis of human osteocalcin by osteoblasts involves vitamin K for the formation of y-carboxylated glutamic acids (Gla) and vitamin D3 for the stimulation of production (3). Osteocalcin has a high afilnity for calcium and exhibits a compact calcium-dependent a-helical conformation, in which the Gla residues promote absorption to hydroxyapatite in the bone matrix (1, 4) . Freshly synthesized osteocalcin is partly secreted into the bloodstream and partly incorporated into the bone matrix. Circulating osteocalcin is associated with changes in the rate of bone turnover in Here we report on the development and characterization of monoclonal antibodies (MAbs) raised against osteocalcin purified from human femoral bones.4 This is the first report of a two-site ELISA based on MAbs that recognize the NH2-terminal sequence aa7-19 and the mid-molecular sequence aa2O-43. We wanted to design an immunoassay that would be independent of the labile six-aa COOH-terminal sequence. We also focused on the stability of human osteocalcin in serum during storage at 4 #{176}C and when monitored in circulation in postmenopausal women undergoing antiresorptive treatment. 
Materials and Methods

Materials
Depletion of Human Osteocalcin from Normal Equine Serum
MAb 504-1 was coupled to a CNBr-activated Sepharose 4B matrix (Pharmacia, Uppsala, Sweden) according to instructions from the manufacturer. The gel matrix was equilibrated at 4 #{176}C with 0.1 moIIL Tris and 0.5 mol/L NaCl, pH 8.3. Heat-inactivated normal equine serum was circulated through the column for 3 days, and the depleted serum was assayed with the N-MID human osteocalcin ELISA.
Two-Site N-MID ELISA for Determining Human Osteocalcin in Serum
High-binding 96-well flat-bottom microtiter plates
Nunc, Roskilde, Denmark), called immunoplates, were coated at 4 #{176}C with Protein A-purified MAb 504-1. The antibody was diluted to 5 mg/L in coating buffer, and 100 L was added to each well. After an overnight incubation the plate was washed five times with washing solution. PBS was added (200 L per well), and the plate was incubated for 1 h. In a second uncoated microtiter plate, the mixing plate (PolySorp; Nunc), 25 L of either standards, control, or unknown samples was added to the appropriate wells, followed by 200 L of PBS-BTES per well. The contents of the wells were mixed for 15 mm; meanwhile, the immunoplate was washed five times with washing solution. To the empty wells of the immunoplate was added 100 L of peroxidase-conjugated Several MAbs were produced (Fig. 1, Table  1 ). MAbs 504-1 and 539-4 were selected for use in the N-MID human osteocalcin ELISA in part because they demonstrated high reactivity to either the midregion or the NH2-terminal part of human osteocalcin, respectively (Fig. 1 (Fig. 2) . The inset in Fig. 2 (mean ± SD) ( Table 3) . The detection limit, defined as the concentration corresponding to the mean absorbance of 20 determinations of the zero standard plus 2 SD, was 2.0 gfL. The imprecision of the assay was <7% (Table 4) .
Serum samples from 40 normal subjects were measured with both the N-MID ELISA and the ELSA-OSTEO IRMA. The two N-MID assays were highly correlated (r = 0.982, P <0.001) (Fig. 3) . The stability of human osteocalcin in serum during storage was examined in the N-MID human osteocalcin ELISA and in the ELSA-NAT-OST IRMA, the latter measuring intact human osteocalcin only. We tested serum taken from blood samples (n = 10) within 1 h of collection and incubated at various times at 4 #{176}C. The mean serum concentration of NH2-terminal midfragment plus intact human osteocalcin, as measured in the N-MID ELISA, decreased only 10% after 7 days of storage (Fig. 4) 
Discussion
